Skip to main content

Resectoscope

Specialized endoscopic instrument combining a continuous-flow sheath, working element, sliding wire-loop electrode, and angled telescope — the operative platform for transurethral resection in the lower urinary tract (TURP, TURBT, bladder-neck incision) and transcervical / intrauterine resection in gynecology (hysteroscopic myomectomy, polypectomy, septum incision, endometrial ablation). The reference instrument against which every newer BPH technology (PUL, water vapor, aquablation, prostatic-artery embolization) and bladder-tumor technique (en-bloc / laser ERBT) is benchmarked.[1][2]

Components​

ComponentDetail
Outer sheathContinuous-flow channel for irrigation inflow and outflow; 24–28 Fr in urology, smaller in gyn
Inner sheath / working elementHouses the cutting loop; spring-loaded thumb-driven mechanism converts hand squeeze into in/out loop motion (newer designs add lateral rotation)
Cutting loop / electrodeWire loop carrying monopolar or bipolar RF energy; vaporization-roller / bar variants for ablation
TelescopeRigid rod-lens (12° or 30°); couples to a video camera
Irrigation systemContinuous-flow (Iglesias 1975) — simultaneous inflow + outflow keeps the field clear at low intracavitary pressure

Monopolar vs Bipolar​

FeatureMonopolarBipolar
IrrigantElectrolyte-free (1.5% glycine, 3% sorbitol)Normal saline
TUR syndrome (dilutional hyponatremia)Real risk (historical 1–18 per 1,000)Near-eliminated (~ 3 per 1,000)[3]
Transfusion29 per 1,00012 per 1,000[3]
Catheterization / irrigation durationReferenceShorter (~ 22 / 9 h less)
Symptom / QoL outcomeEquivalentEquivalent

Bipolar is the dominant modern platform because it permits saline irrigation and substantially reduces TUR-syndrome and bleeding events.[3][4]

Reconstructive-Urology and Functional-Urology Uses​

The resectoscope is encountered in WARWIKI scope across three pathways:

TURP — reference standard for BPH​

  • Indications — moderate-to-severe LUTS refractory to medical therapy, refractory retention, recurrent UTI from BPO, bladder stones, gross hematuria of BPH origin, renal insufficiency from BPO.[1][2]
  • Outcomes — mean IPSS improvement 12–15 points, mean Qmax + ~ 162%; retreatment rate 3–14.5% at 5 years.[2][5]
  • Position in the BPH algorithm — EAU 30–80 mL prostate; AUA 2026 reference standard against which water vapor, PUL, aquablation, PAE, and HoLEP / ThuLEP are benchmarked.[1][2]

TURBT — out-of-scope as a primary oncology topic, included briefly because the instrument is the same​

  • Quality determinants that drive RU/urogyn-relevant downstream decisions: detrusor muscle in specimen (only ~ 52% of specimens contain detrusor; inadequate staging HR 1.48 for CSS); both 30° and 70° lenses for complete inspection; repeat TURBT at 6 weeks for incomplete resection, no muscle in HG specimen, ≥ 3 cm / multifocal, or any T1 — 51% residual disease, 8% upstaging to MIBC.[6][7]
  • En-bloc resection (ERBT) — Teoh 2024 phase-3 RCT (≤ 3 cm tumors) 1-yr recurrence 29% vs 38% with conventional TURBT (p = 0.007); Xu 2025 meta of 12 RCTs (n = 2,097) confirms higher detrusor sampling (OR 1.90), lower perforation (OR 0.30), lower obturator-reflex (OR 0.18). EAU now supports ERBT as an option for NMIBC.[8][9][10]

Hysteroscopic resectoscope — urogyn-shared use​

  • Submucosal myoma, endometrial polyp, uterine septum, intrauterine adhesions, endometrial ablation — ACOG endorses direct hysteroscopic removal over blind procedures for polypectomy; the mini-resectoscope extends feasibility to the office setting.[11][12]
  • Loop resectoscope vs hysteroscopic tissue-removal systems (morcellators) — morcellators are faster and more complete for polyps and type 0–I myomas; the loop resectoscope retains the advantage for type II (deeply embedded) myomas where loop dissection is needed.[11]

Complications of TURP — the RU-relevant Long-Tail​

Modern TURP complication rates have fallen substantially with bipolar technology, smaller sheaths, and video systems. The events most relevant to reconstructive practice downstream are urethral stricture, bladder-neck contracture, and post-prostatectomy incontinence:[2][3][13][14]

ComplicationContemporary rateReconstructive implication
Mortality0.1%—
TUR syndrome0–1.4% (near-zero bipolar)—
Transfusion0.4–2.9%—
Clot retention2–5%May need 3-way irrigation catheter
Urinary retention after catheter removal3–5.8%Often detrusor failure, not incomplete resection
Urethral stricture2.2–9.8%Drives downstream DVIU or urethroplasty; see Sachse urethrotome
Bladder-neck contracture0.3–9.2%Drives transurethral incision / resection of BNC; see Balloon Dilator; risk factors include small prostate and prior prostatitis[14]
Retrograde ejaculation~ 65%Expected; counsel preoperatively
Erectile dysfunction~ 6.5–10%—
Stress incontinence (late)0.5%Late SUI may need AUS, sling, or PAUS; early urge incontinence ~ 30–40% but transient
Retreatment3–14.5% at 5 yr—

For the reconstructive surgeon, post-TURP urethral stricture, BNC, and post-prostatectomy SUI are the operative downstream consequences that bring these patients to urethroplasty, transurethral BNC incision, AUS, and sling.

TURBT-Specific Technical Considerations​

  • Obturator-nerve reflex during lateral-wall resection causes sudden adductor contraction and risks bladder perforation — mitigated by obturator-nerve block, bipolar energy, or muscle relaxation under GA.[15]
  • Enhanced visualization — blue-light PDD and NBI improve detection of CIS / flat lesions missed under white light; see the rigid and flexible cystoscope pages for the BLC / NBI data.[6][16]
  • En-bloc resection energy sources — bipolar, Ho:YAG, thulium, KTP / GreenLight, or hybrid knife; laser and hybrid-knife platforms show superior outcomes in network meta.[17]

Technique — TURP​

  1. Spinal or general anesthesia; dorsal lithotomy; cystoscopic survey.
  2. Continuous-flow video resectoscope (24–28 Fr) with bipolar working element (preferred) and 12° / 30° telescope.
  3. Systematic resection from bladder neck to verumontanum, leaving the verumontanum and external sphincter intact.
  4. Chips evacuated with Ellik evacuator or Toomey syringe; average resected mass ~ 28 g; incidental prostate carcinoma in ~ 10% of specimens.[13]
  5. 24–26 Fr 3-way Foley with 30 mL balloon for fossa tamponade and CBI for 24–72 h.

Limitations​

  • TUR syndrome risk persists with monopolar — bipolar is the safer modern default.
  • Prostate size ceiling — large glands (typically > 80–100 g) increasingly handled by enucleation (HoLEP / ThuLEP) or open simple prostatectomy.
  • Reconstructive sequelae — urethral stricture and bladder-neck contracture are the late events that bring TURP patients to RU clinic.
  • Hysteroscopic mini-resectoscope has expanded office feasibility but still requires distending media monitoring.

See also: Rigid Cystoscope, Flexible Cystoscope, Sachse Urethrotome (DVIU), Balloon Dilator, Three-Way Catheter (CBI), Electrosurgical Pencil, Bovie Tips.

References​

1. Wei JT, Dauw CA, Brodsky CN. "Lower urinary tract symptoms in men." JAMA. 2025;334(9):809–21. doi:10.1001/jama.2025.7045

2. Goueli R, Badlani GH, Welliver C, et al. "Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline (2026) part III: procedural / surgical management." J Urol. 2026. doi:10.1097/JU.0000000000005099

3. Alexander CE, Scullion MM, Omar MI, et al. "Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction." Cochrane Database Syst Rev. 2019;12:CD009629. doi:10.1002/14651858.CD009629.pub4

4. Mamoulakis C, Ubbink DT, de la Rosette JJ. "Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials." Eur Urol. 2009;56(5):798–809. doi:10.1016/j.eururo.2009.06.037

5. Franco JV, Jung JH, Imamura M, et al. "Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis." Cochrane Database Syst Rev. 2021;7:CD013656. doi:10.1002/14651858.CD013656.pub2

6. Lenis AT, Lec PM, Chamie K, Mshs MD. "Bladder cancer: a review." JAMA. 2020;324(19):1980–91. doi:10.1001/jama.2020.17598

7. National Comprehensive Cancer Network. "Bladder Cancer." NCCN Clinical Practice Guidelines in Oncology. Updated 2026.

8. Teoh JY, Cheng CH, Tsang CF, et al. "Transurethral en bloc resection versus standard resection of bladder tumour: a randomised, multicentre, phase 3 trial." Eur Urol. 2024;86(2):103–11. doi:10.1016/j.eururo.2024.04.015

9. Xu Z, Wang Q, Li B, et al. "An updated systematic review, meta-analysis, and trial sequential analysis of the efficacy and safety of en bloc transurethral resection vs conventional transurethral resection for nonmuscle-invasive bladder tumor." Int J Surg. 2025;111(4):3061–77. doi:10.1097/JS9.0000000000002291

10. Li DX, Yu QX, Wu RC, et al. "Efficiency of transurethral en-bloc resection vs conventional transurethral resection for non-muscle-invasive bladder cancer: an umbrella review." Cancer Med. 2024;13(11):e7323. doi:10.1002/cam4.7323

11. Deutsch A, Sasaki KJ, Cholkeri-Singh A. "Resectoscopic surgery for polyps and myomas: a review of the literature." J Minim Invasive Gynecol. 2017;24(7):1104–10. doi:10.1016/j.jmig.2017.08.645

12. Etrusco A, Laganà AS, Chiantera V, et al. "Efficacy, safety, and feasibility of the treatment of intrauterine pathologies with the mini-resectoscope: a systematic review." Int J Gynaecol Obstet. 2024;166(2):527–37. doi:10.1002/ijgo.15393

13. Reich O, Gratzke C, Bachmann A, et al. "Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients." J Urol. 2008;180(1):246–9. doi:10.1016/j.juro.2008.03.058

14. Goßler C, Pfänder F, Haas M, et al. "Risk factors for bladder neck contracture after transurethral resection of the prostate." Prostate. 2023;83(11):1020–7. doi:10.1002/pros.24543

15. Wu J, Gao Y, Xiong Z, et al. "Comparison of different methods of obturator nerve block in transurethral resection of bladder tumors: a systematic review and network meta-analysis." Cancer Med. 2023;12(5):5420–35. doi:10.1002/cam4.5364

16. Richards KA, Smith ND, Steinberg GD. "The importance of transurethral resection of bladder tumor in the management of non-muscle invasive bladder cancer: a systematic review of novel technologies." J Urol. 2014;191(6):1655–64. doi:10.1016/j.juro.2014.01.087

17. Mi G, Ma Y, Liu L, Liao B, Wang K. "Optimal energy source selection strategies for en bloc resection in non-muscle invasive bladder cancer: a systematic review and network meta-analysis." World J Urol. 2025;43(1):155. doi:10.1007/s00345-025-05513-8